Products & Services · Total Revenue
FUMADERM And ADUHELM — Total Revenue
Year-over-year, this metric declined by 100.0%, from $1.70M to $0.00. Over 3 years (FY 2022 to FY 2025), FUMADERM And ADUHELM — Total Revenue shows a downward trend with a -45.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ1 2022
Last reportedQ1 2026
Rolls up toTotal Revenue
How to read this metric
An increase suggests sustained or growing market demand for these specific therapies, while a decrease indicates product lifecycle maturity, competitive displacement, or strategic phase-outs.
Detailed definition
This metric represents the total net sales generated from the specific product portfolio consisting of Fumaderm and Aduh...
Peer comparison
Similar to legacy product revenue or non-core asset performance metrics reported by other large-cap biopharmaceutical companies.
Metric ID:
biib_segment_fumaderm_and_aduhelm_total_revenueHistorical Data
17 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $5.00M | $2.80M | $3.10M | $2.10M | $2.40M | $4.30M | $3.70M | $0.00 | $2.80M | $2.70M | $2.10M | $2.70M | $1.70M | $400.00K | $0.00 | $0.00 | $0.00 |
| QoQ Change | — | -44.0% | +10.7% | -32.3% | +14.3% | +79.2% | -14.0% | -100.0% | — | -3.6% | -22.2% | +28.6% | -37.0% | -76.5% | -100.0% | — | — |
| YoY Change | — | — | — | — | -52.0% | +53.6% | +19.4% | -100.0% | +16.7% | -37.2% | -43.2% | — | -39.3% | -85.2% | -100.0% | -100.0% | -100.0% |
Range$0.00 – $5.00M
CAGR-100.0%
Avg YoY Growth-47.3%
Median YoY Growth-47.6%
Current Streak5 quarters decline
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Biogen's fumaderm and aduhelm — total revenue?
- Biogen (BIIB) reported fumaderm and aduhelm — total revenue of $0.00 in Q1 2026.
- How has Biogen's fumaderm and aduhelm — total revenue changed year-over-year?
- Biogen's fumaderm and aduhelm — total revenue decreased by 100.0% year-over-year, from $1.70M to $0.00.
- What is the long-term trend for Biogen's fumaderm and aduhelm — total revenue?
- Over 3 years (2022 to 2025), Biogen's fumaderm and aduhelm — total revenue has grown at a -45.5% compound annual growth rate (CAGR), from $13.00M to $2.10M.
- What does fumaderm and aduhelm — total revenue mean?
- The total revenue generated from the sale of the Fumaderm and Aduhelm product line.